The potential of nearly 300 next generation immune checkpoint modulators for the treatment (Roots)

Over time, significant strides have been made in immune checkpoint research, resulting in the discovery of several inhibitory (LAG-3, TIM-3, TIGIT, VISTA and B7-H3) and stimulatory receptors (OX40, ICOS, GITR, 4-1BB and CD40), which are being investigated as potential targets for therapy development. Further, studies of combinatorial immune checkpoint blockade / co-stimulation, targeting newly identified checkpoints along with known checkpoint inhibitor therapies, have demonstrated promising clinical outcomes as well.

 

To order this 350+ page report, which features 140+ figures and 170+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html

 

The USD 12 billion (by 2030) financial opportunity within the next generation immune checkpoint modulators market has been analyzed across the following segments:

Target Disease Indication

Breast CancerChronic Lymphocytic LeukemiaColorectal CancerHead and Neck CancerLung CancerLupus NephritisMelanomaMultiple MyelomaPrimary Sjögren's SyndromeOthers

Target Immune Checkpoint

B7-H3CD38CD40CD47Others

Mechanism of Action

InhibitoryStimulatory

Therapeutic Modality

Monoclonal AntibodySmall Molecule

Type of Therapy

MonotherapyCombination Therapy

Route of Administration

IntravenousSubcutaneousOthers

Key Geographical Regions

North AmericaEuropeAsia-Pacific and the Rest of the World

 

The Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030. report features the following companies, which we identified to be key players in this domain: 

Bristol Myers Squibb

GlaxoSmithKline

Incyte

Novartis

Trillium Therapeutics

 

Table of Contents

 

1. Preface

2. Executive Summary

3. Introduction

4. Current Market Landscape: Clinical and Preclinical Molecules

5. Market Landscape: Therapies Targeting Cd47

6. Market Landscape: Therapies Targeting 4-1bb

7. Clinical Trial Analysis

8. Company Profiles: Next Generation Inhibitors and Stimulators

9. Academic Grants Analysis

10. Partnerships and Collaborations

11. Target Competitiveness Analysis

12. Big Pharma Initiatives

13. Market Forecast and Opportunity Analysis

14. Concluding Remarks

15. Executive Insights

16. Appendix 1: Tabulated Data

17. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]